NEW YORK (GenomeWeb News) – Laboratory Corporation of America is offering Roche's new Cobas AmpliPrep/Cobas TaqMan HCV test, which the US Food and Drug Administration cleared for marketing in October 2008.

The test is fully automated and uses Roche's proprietary real-time PCR technology to quantify the amount of virus in an individual's blood. Physicians can use it to monitor viral load at baseline and during treatment to help determine the effectiveness of therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.